Thelansis

 Follicular lymphoma (FL), often called indolent lymphoma, is the second most prevalent type of non-Hodgkin lymphoma (NHL). Despite treatment, a considerable number of FL patients experience treatment failure, leading to classification as refractory lymphomas. Others initially respond positively but subsequently display signs of recurrent tumor growth, termed relapsed follicular lymphoma. The advanced-stage disease is typically deemed incurable, marked by a protracted pattern of relapse and remission. A notable subset of patients, particularly those with transformed or rapidly progressive disease, face less favorable outcomes. Bone marrow biopsy is typically reserved for individuals presenting with unexplained cytopenias. FL has the potential to progress into a more aggressive form of lymphoma, such as diffuse large B-cell lymphoma. Thus, biopsy remains crucial for diagnosing this transformation upon relapse. The advent of anti-CD20 monoclonal antibodies (mAbs) like rituximab and, ...

  Follicular lymphoma (FL), commonly referred to as indolent lymphoma, is the second most common type of non-Hodgkin lymphoma (NHL). After treatment, many FL patients fail to respond, and these tumors are categorized as refractory lymphomas. Some react with an initial positive change but then develop signs of recurrent tumor, called relapsed follicular lymphoma. Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. The introduction of anti-CD20 monoclonal antibodies (mAb) such as rituximab and, more recently, type II anti-CD20 mAb, obinutuzumab, has revolutionized the management of FL, and anti-CD20 antibodies will likely remain at the forefront of the FL treatment armamentarium. But more recent insights demonstrating the intricate relationship between the FL tumor cell and its distinct immune microenvironmen...